🔍 Description:

FOXO4-DRI is a synthetic peptide designed to disrupt the interaction between the FOXO4 protein and p53, a critical regulator of cellular senescence. By targeting and eliminating senescent cells, FOXO4-DRI has the potential to reverse age-related tissue damage, promote tissue regeneration, and extend lifespan.

💪 Health Benefits:

– Anti-Aging: Promotes tissue regeneration by selectively targeting and eliminating senescent cells, which accumulate with age and contribute to cellular dysfunction.

– Longevity: May extend lifespan and improve overall health by delaying the onset of age-related cellular damage and promoting the regeneration of healthy tissues.

– Disease Prevention: Potentially reduces the risk of age-related diseases, including cancer, by eliminating damaged cells that could contribute to disease progression.

💉 Dosing/Administration:

– Animal Study Protocol:

  – **Dosage:**adapted to humans at 0 .42 mg/kg administered three times with one day in between (Day 1, 3, 5)

  – Administration Method: Subcutaneous injection.

  – Cycling: Twice per year is sometimes suggested.

– LaValle Protocol:

  – Dosage: . 4mg SQ every 3 days for 4-6 weeks.  . May repeat 1-3 times a year

  – Administration Method: Subcutaneous injection.

– dosing FOXO4 with MOTS-c or Humanin peptides can improve FOXO4’s ability to patrol for and eliminate senescent cells.

⚠️ Side Effects and Safety:

– Common Side Effects: Not well-documented due to its experimental nature; potential side effects may include cellular-level disruptions.

– Safety Profile: This peptide is experimental and should only be used under the guidance of a healthcare provider or as part of a research protocol. Long-term safety is not yet established.

– Other Synolytics such as Rapamycin should be discontinued one month before commencing a FOXO4-dri cycle.

Note:   Healthy cells in organs that have limited regeneration cycles may be “taken out”.   This may indicate lifespan vs. healthspan tradeoffs.   Also there are reports that cells in reproductive organs may be especially targeted.   If sources for these concerns are provided this post will be updated.

Here’s a summary of the key points from this research article:

The study focused on FOXO4-DRI, a peptide that targets senescent Leydig cells in the testes to potentially treat age-related testosterone deficiency (late-onset hypogonadism).

Key findings:

FOXO4 was specifically expressed in Leydig cells of human testes

FOXO4 showed nuclear localization in Leydig cells of older men, associated with decreased testosterone synthesis

In vitro, FOXO4 maintained viability of senescent Leydig cells

FOXO4-DRI induced apoptosis selectively in senescent Leydig cells by disrupting FOXO4-p53 interaction

In aged mice, FOXO4-DRI treatment:

Increased serum testosterone levels

Improved testicular microenvironment

Reduced markers of cellular senescence in testes

Decreased levels of pro-inflammatory factors

The researchers suggest FOXO4-DRI could potentially treat late-onset hypogonadism by selectively eliminating senescent Leydig cells and improving the testicular environment.

Limitations noted include:

Exact mechanism of testosterone increase not fully elucidated

Long-term effects not yet evaluated

Potential off-target effects of systemic administration need further study

The authors conclude FOXO4-DRI shows promise as a novel therapeutic approach for age-related testosterone deficiency, but further research is needed.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053614/